25.93
+0.08(+0.31%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
108
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | 681,754 | 1959 |
| Anne Lesage | Chief Early Development Officer | 0 | 1961 |
| Peng Lu | Chief Medical Officer | 0 | 1978 |
| Stefan Abele | Chief Technology Operations Officer | 0 | 1970 |
| Maryann Cimino | Director of Corporate Relations | 0 | N/A |
| David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 0 | 1954 |
| Wim Souverijns | Chief Commercial Officer | 0 | 1971 |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | 0 | 1981 |
| Annick Deschoolmeester | Chief Human Resources Officer | 0 | 1973 |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
